TIWARI, RAHUL
TIWARI, RAHUL
Architettura (DiDA)
Mostra
records
Risultati 1 - 2 di 2 (tempo di esecuzione: 0.003 secondi).
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study
2021 Passamonti F.; Gupta V.; Martino B.; Foltz L.; Zaritskey A.; Al-Ali H.K.; Tavares R.; Maffioli M.; Raanani P.; Giraldo P.; Griesshammer M.; Guglielmelli P.; Bouard C.; Paley C.; Tiwari R.; Vannucchi A.M.
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
2021 Cervantes F.; Ross D.M.; Radinoff A.; Palandri F.; Myasnikov A.; Vannucchi A.M.; Zachee P.; Gisslinger H.; Komatsu N.; Foltz L.; Mannelli F.; Passamonti F.; Gilotti G.; Sadek I.; Tiwari R.; Zor E.; Al-Ali H.K.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study | 2021 | Passamonti F.; Gupta V.; Martino B.; Foltz L.; Zaritskey A.; Al-Ali H.K.; Tavares R.; Maffioli M.; Raanani P.; Giraldo P.; Griesshammer M.; Guglielmelli P.; Bouard C.; Paley C.; Tiwari R.; Vannucchi A.M. | |
| Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study | 2021 | Cervantes F.; Ross D.M.; Radinoff A.; Palandri F.; Myasnikov A.; Vannucchi A.M.; Zachee P.; Gisslinger H.; Komatsu N.; Foltz L.; Mannelli F.; Passamonti F.; Gilotti G.; Sadek I.; Tiwari R.; Zor E.; Al-Ali H.K. |